Non-invasive Assessment of Liver Fibrosis in a French Cohort of Pediatric Patients With Type III Glycogen Storage Disease: Current State and Perspectives

Patients with type III glycogen storage disease (GSDIII) can develop liver fibrosis, which can be complicated by liver failure or even hepatocellular carcinoma. Since the beginning of the 21st century, non-invasive techniques for assessing fibrosis, such as liver elastography, have been developed. These techniques often make it possible to avoid liver biopsies during patient follow-up and have already been validated in the management of several diseases in adults. These techniques are also beginning to be recommended for monitoring certain chronic liver diseases in children.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Liver Fibrosis Carbohydrate Metabolism, Inborn Errors Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Fibrosis Genetic Diseases, Inborn Glycogen Storage Disease Glycogen Storage Disease Type III Liver Cirrhosis Liver Diseases Metabolic Diseases Metabolism, Inborn Errors Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

1 month–21 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de pédiatrie 1 - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Camille WICKER, MD

CONTACT

[email protected]

33 3 88 12 77 12

Camille WICKER, MD

PRINCIPAL_INVESTIGATOR

Maxime BINET, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Minors: from birth to 17 years
Adults: 18 to 21 years
Subjects being monitored for type III glycogen storage disease and having had at least one liver elastography measurement during their follow-up.

Exclusion criteria

Patients monitored for type III glycogen storage disease but who had never undergone liver elastography during their follow-up.

Treatment and study plan

Primary outcomes

Liver elastography values

Time frame: 1 hour after consultation
Liver fibrosis is classified into four stages, from 0 to 4:
- F0 corresponds to the absence of fibrosis
- F4 corresponds to established cirrhosis.

Study contacts

Contact information is provided by the study sponsor or research team.

Camille WICKER, MD

CONTACT

[email protected]

33 3 88 12 77 12

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: HEPAGLY

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Dec 24, 2025
Registry last updated: Dec 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting